摘要
目的探讨安罗替尼联合紫杉醇+卡铂治疗晚期肺腺癌的临床效果。方法选择安徽省宣城市人民医院于2018年5月~2019年9月收治的驱动基因阴性的晚期肺腺癌患者80例,按照随机数字表法分为对照组和治疗组,每组各40例。对照组给予紫杉醇+卡铂治疗,治疗组给予安罗替尼联合紫杉醇+卡铂治疗,21 d为1个疗程,两组患者均连续治疗3个疗程。比较两组患者治疗后临床疗效,治疗前后KPS评分、血清癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、血管内皮生长因子(VEGF)水平以及治疗期间毒副反应发生情况。结果治疗组总缓解率明显高于对照组,差异有统计学意义(P <0.05)。两组患者治疗后KPS评分均高于治疗前,且治疗组高于对照组,差异有统计学意义(P <0.05)。两组患者治疗后血清CEA、NSE及VEGF水平均低于治疗前,且治疗组低于对照组,差异有统计学意义(P <0.05)。两组患者治疗期间毒副反应发生率比较,差异无统计学意义(P> 0.05)。结论安罗替尼联合紫杉醇+卡铂治疗晚期肺腺癌的临床疗效显著,能够明显提高患者生活质量,降低血清CEA、NSE、VEGF水平,且安全性较好。
Objective To explore the clinical effect of Anlotinib combined with paclitaxel and Carboplatin in the treatment of advanced lung adenocarcinoma. Methods A total of 80 patients with negative driving gene of advanced lung adenocarcinoma who were admitted to the People′s Hospital of Xuancheng City of Anhui Province from May 2018 to September 2019 were selected and divided into control group and treatment group according to the random number table method, with 40 cases in each group. The control group was given paclitaxel + carboplatin treatment, while the treatment group was given Anrotinib combined with paclitaxel + Carboplatin treatment, 21 d was a course of treatment,while both groups were given 3 courses of treatment continuously. The clinical efficacy of the two groups after treatment, KPS scores, serum carcinoembryonic antigen(CEA), neuron-specific enolase(NSE), vascular endothelial growth factor(VEGF) levels and the incidence of toxic and side effects during treatment were compared before and after treatment. Results The total remission rate of the treatment group was significantly higher than that of the control group,and the difference was statistically significant(P < 0.05). The KPS scores of the two groups after treatment were higher than that before treatment, while the treatment group was higher than the control group, the differences were statistically significant(P < 0.05). The levels of serum CEA, NSE and VEGF after treatment in the two groups were lower than those before treatment, while the treatment group was lower than the control group, the differences were statistically significant(P < 0.05). There was no statistically significant difference in the incidence of side effects during treatment between the two groups(P > 0.05). Conclusion Anlotinib combined with paclitaxel and Carboplatin has a significant clinical effect in the treatment of advanced lung adenocarcinoma, which can significantly improve the patient′s quality of life, reduce serum CEA, NSE, VEGF levels, and has good safety.
作者
舒桂君
朱永东
解华
SHU Guijun;ZHU Yongdong;XIE Hua(Department of Oncology,the People′s Hospital of Xuancheng City,Anhui Province,Xuancheng242000,ChinaObjective To explore the clinical effect of Anlotinib combined with paclitaxel and Carboplatin in the)
出处
《中国医药导报》
CAS
2020年第12期137-140,共4页
China Medical Herald
基金
安徽省科技计划项目(1706c08532)。
关键词
晚期肺腺癌
安罗替尼
紫杉醇
卡铂
Advanced lung adenocarcinoma
Anlotinib
Paclitaxel
Carboplatin
